HomeCompareXENT vs PLD

XENT vs PLD: Dividend Comparison 2026

XENT yields 7.08% · PLD yields 3.10%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PLD wins by $5.88M in total portfolio value· pulled ahead in Year 2
10 years
XENT
XENT
● Live price
7.08%
Share price
$28.24
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$32.0K
Annual income
$1,110.32
Full XENT calculator →
PLD
PLD
● Live price
3.10%
Share price
$132.18
Annual div
$4.10
5Y div CAGR
74.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$5.91M
Annual income
$4,750,725.19
Full PLD calculator →

Portfolio growth — XENT vs PLD

📍 PLD pulled ahead of the other in Year 2

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodXENTPLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, XENT + PLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
XENT pays
PLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

XENT
Annual income on $10K today (after 15% tax)
$601.98/yr
After 10yr DRIP, annual income (after tax)
$943.77/yr
PLD
Annual income on $10K today (after 15% tax)
$263.66/yr
After 10yr DRIP, annual income (after tax)
$4,038,116.41/yr
At 15% tax rate, PLD beats the other by $4,037,172.64/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of XENT + PLD for your $10,000?

XENT: 50%PLD: 50%
100% PLD50/50100% XENT
Portfolio after 10yr
$2.97M
Annual income
$2,375,917.75/yr
Blended yield
80.00%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PLD right now

XENT
No analyst data
PLD
Analyst Ratings
25
Buy
16
Hold
1
Sell
Consensus: Buy
Price Target
$136.00
+2.9% upside vs current
Range: $119.00 — $155.00
Altman Z
1.9
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

XENT buys
0
PLD buys
0
No recent congressional trades found for XENT or PLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricXENTPLD
Forward yield7.08%3.10%
Annual dividend / share$2.00$4.10
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%74.4%
Portfolio after 10y$32.0K$5.91M
Annual income after 10y$1,110.32$4,750,725.19
Total dividends collected$9.1K$5.78M
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: XENT vs PLD ($10,000, DRIP)

YearXENT PortfolioXENT Income/yrPLD PortfolioPLD Income/yrGap
1$11,408$708.22$11,241$540.96+$167.00XENT
2← crossover$12,962$755.09$13,019$991.13$57.00PLD
3$14,671$801.80$15,801$1,870.97$1.1KPLD
4$16,546$848.15$20,609$3,701.21$4.1KPLD
5$18,598$893.98$29,919$7,867.97$11.3KPLD
6$20,839$939.12$50,631$18,617.74$29.8KPLD
7$23,282$983.44$105,528$51,352.20$82.2KPLD
8$25,938$1,026.81$287,364$174,449.42$261.4KPLD
9$28,823$1,069.13$1,081,760$774,280.77$1.05MPLD
10$31,951$1,110.32$5,908,209$4,750,725.19$5.88MPLD

XENT vs PLD: Complete Analysis 2026

XENTStock

Intersect ENT, Inc. operates as an ear, nose, and throat (ENT) medical technology company in the United States. The company offers PROPEL, a steroid releasing implant to open the surgically enlarged sinus; PROPEL Mini, a releasing implant to treat patients undergoing frontal sinus surgery; and PROPEL Contour, a steroid releasing implant for the treatment of frontal and maxillary sinus ostia, or openings, of the dependent sinuses. It also provides SINUVA, a steroid releasing implant for the treatment of patients in the physician office setting; VENSURE Navigable and Stand-alone balloon, a sterile and single-use device, used to access and treat frontal, sphenoid sinus, and maxillary ostia in adults using a trans-nasal approach; and CUBE Navigation System, a virtual guidance platform for high precision ENT and ENT related skull-base surgeries. The company was formerly known as Sinexus, Inc. and changed its name to Intersect ENT, Inc. in November 2009. Intersect ENT, Inc. was incorporated in 2003 and is headquartered in Menlo Park, California.

Full XENT Calculator →

PLDREIT

Prologis, Inc. is the global leader in logistics real estate with a focus on high-barrier, high-growth markets. As of December 31, 2020, the company owned or had investments in, on a wholly owned basis or through co-investment ventures, properties and development projects expected to total approximately 984 million square feet (91 million square meters) in 19 countries. Prologis leases modern logistics facilities to a diverse base of approximately 5,500 customers principally across two major categories: business-to-business and retail/online fulfillment.

Full PLD Calculator →
📬

Get this XENT vs PLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

XENT vs SCHDXENT vs JEPIXENT vs OXENT vs KOXENT vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.